Juvenile Arthritis News

A safety profile consistent with that of the historical safety data of Remicade was observed among patients with rheumatoid arthritis and ankylosing spondylitis treated with the Remicade biosimilar, Remsima, according to analysis results.

The Biosimilars Forum announced its support for a letter from Congress members to Andrew Slavitt, acting administrator for CMS, regarding proposed provisions for the assignment of billing codes to biosimilars. The letter was cosigned by House Energy and Commerce Committee members Reps. Joe Barton (R-Tex.) and Anna Eshoo (D-Calif.) and a delegation of 33 House members.

High-intensity interval training was well-tolerated by women with rheumatoid arthritis and adults with juvenile-onset idiopathic arthritis and may be beneficial, according to the results of a study.

A small number of patients developed a malignancy while receiving anti-tumor necrosis factor-alpha treatment for an autoimmune disease, and most who did discontinued treatment with biologic agents, according to the results of a study.

Childhood antibiotic use may lead to cases of juvenile idiopathic arthritis by disturbing the human microbiome, according to a recent study in Pediatrics.

The chemokines CXCL10 and CXCL13 may be biomarkers associated with adult onset Still’s disease and disease activity, according to recently presented data.

Patients with familial Mediterranean fever may have comorbid rheumatic diseases that are not prevented with adequate colchicine therapy, according to study findings.

Hepatitis B virus reactivation was not prevalent among rheumatologic patients with previously resolved hepatitis B virus infection and rheumatologic indications for long-term biologic therapies, indicating that universal prophylaxis might not be cost-effective in this type of clinical setting, according to data published in Hepatology.

Musculoskeletal ultrasound imaging may be a complementary tool in the assessment and ongoing monitoring of symptoms in children with reactive arthritis, according to recently presented data.

Patients with a rheumatic or immune disease, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease or ulcerative colitis, who switched anti-tumor necrosis factor-alpha agents for non-medical reasons experienced reduced efficacy, an increase in side effects, subsequent treatment changes and greater health care utilization, according to research by Allan Gibofsky, MD, and colleagues.